World neurosurgery · 2016
Tumor Location and Survival Outcomes in Adult Patients with Supratentorial Glioblastoma by Levels of Toll-Like Receptor 9 Expression.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mu Linsen, Wang Yongzhi, Wang Yonggang, Zhang Hongbo, Shang Dewei, Tan Fuqiang, Li Yan, Chen Xuzhu
Аннотация
BACKGROUND: Toll-like receptor 9 (TLR9) is a key immunotherapy target for glioblastoma (GBM). This study explored the correlation of TLR9 expression with tumor location and survival outcomes in patients with supratentorial GBM.
METHODS: We retrospectively identified 46 patients with supratentorial GBMs and divided them into those with high TLR9 (TRL9High) and low TLR9 (TRL9Low) levels. The 2 groups were compared by patients' ages, sex, preoperative Karnofsky Performance Scale (KPS) score, resection extent, tumor location, progression-free survival (PFS), and overall survival (OS).
RESULTS: The TLR9 expression percentages for the GBM specimens were TRL9High: 72% (33/46) and TRL9Low: 28% (13/46). The 2 groups showed no differences in patient age (P = 0.147) and sex (χ2 = 0.002, P = 0.966), preoperative KPS score (χ2 = 0.033, P = 0.855), or resection extent (χ2 = 2.405, P = 0.121). Location differed significantly, with 85% (11/13) of TRL9Low tumors in the left hemisphere and 45% (15/33) of TRL9High tumors on the same side (χ2 = 5.82, P = 0.016). The TRL9Low group had a median PFS of 612 days (range, 77-926 days), significantly longer than the TRL9High group (355 days; range, 105-861 days; P = 0.042). Median OS of the TRL9Low group (733 days; range, 163-969 days) was also significantly longer than in the TRL9High group (396 days; range, 135-1024 days; P = 0.020).
CONCLUSIONS: Patients with TRL9Low supratentorial GBM tend to have longer survival than those with higher TLR9 expression. Such tumors show a location preference for the left hemisphere.
METHODS: We retrospectively identified 46 patients with supratentorial GBMs and divided them into those with high TLR9 (TRL9High) and low TLR9 (TRL9Low) levels. The 2 groups were compared by patients' ages, sex, preoperative Karnofsky Performance Scale (KPS) score, resection extent, tumor location, progression-free survival (PFS), and overall survival (OS).
RESULTS: The TLR9 expression percentages for the GBM specimens were TRL9High: 72% (33/46) and TRL9Low: 28% (13/46). The 2 groups showed no differences in patient age (P = 0.147) and sex (χ2 = 0.002, P = 0.966), preoperative KPS score (χ2 = 0.033, P = 0.855), or resection extent (χ2 = 2.405, P = 0.121). Location differed significantly, with 85% (11/13) of TRL9Low tumors in the left hemisphere and 45% (15/33) of TRL9High tumors on the same side (χ2 = 5.82, P = 0.016). The TRL9Low group had a median PFS of 612 days (range, 77-926 days), significantly longer than the TRL9High group (355 days; range, 105-861 days; P = 0.042). Median OS of the TRL9Low group (733 days; range, 163-969 days) was also significantly longer than in the TRL9High group (396 days; range, 135-1024 days; P = 0.020).
CONCLUSIONS: Patients with TRL9Low supratentorial GBM tend to have longer survival than those with higher TLR9 expression. Such tumors show a location preference for the left hemisphere.